Literature DB >> 17971006

Basic fibroblast growth factor reduces scar formation in acute incisional wounds.

Ichiro Ono1, Yoshikiyo Akasaka, Risa Kikuchi, Akiko Sakemoto, Takafumi Kamiya, Toshiharu Yamashita, Kowichi Jimbow.   

Abstract

In order to identify a means to reduce scar formation of the skin after incision, this study examined the effect of local administration of basic fibroblast growth factor (bFGF) in humans. bFGF was administered to a sutured wound immediately after an operation. The drug was injected once into the dermis of the margins of wounds using a 27G needle or rinsing after performing dermostitches. The lengths of the treated wounds varied from 1 to 32 cm, and the subjects were 2-86 years old. Sutured wounds after excision of skin tumors from the face, trunk, and limbs and sutured wounds such as those at the donor sites of full-thickness skin grafts were treated with low-dose bFGF injections (0.1 microg/cm wound; Group 2), high-dose bFGF injections (1 microg/cm wound; Group 3), and rinsed with high-dose bFGF (1 microg/cm wound; Group 4). No patient treated with bFGF had hypertrophic scars, while some patients had hypertrophic or very wide scars in the control group (Group 1), and the ratios of minimum scarring of Group 2 (p<0.001), Group 3 (p<0.0001), and Group 4 (p<0.0001) were statistically significantly higher than those of Group 1. Postoperative administration of bFGF inhibited hypertrophic scarring and widening of remaining scars without any serious side effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17971006     DOI: 10.1111/j.1524-475X.2007.00293.x

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  27 in total

1.  Innovative therapies in the treatment of keloids and hypertrophic scars.

Authors:  Martha H Viera; Sadegh Amini; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-05

2.  Topical application of basic fibroblast growth factor reduces esophageal stricture and esophageal neural damage after sodium hydroxide-induced esophagitis in rats.

Authors:  Yuichi Okata; Chieko Hisamatsu; Eiji Nishijima; Yutaka Okita
Journal:  Pediatr Surg Int       Date:  2012-01       Impact factor: 1.827

Review 3.  [Bases and methods of suturing].

Authors:  P M Vogt; M A Altintas; C Radtke; M Meyer-Marcotty
Journal:  Chirurg       Date:  2009-05       Impact factor: 0.955

Review 4.  Fine-tuning vascular fate during endothelial-mesenchymal transition.

Authors:  Lin Xiao; Andrew C Dudley
Journal:  J Pathol       Date:  2016-11-10       Impact factor: 7.996

Review 5.  Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature.

Authors:  David M Dolivo
Journal:  J Mol Med (Berl)       Date:  2022-04-28       Impact factor: 4.599

6.  A rat excised larynx model of vocal fold scar.

Authors:  Nathan V Welham; Douglas W Montequin; Ichiro Tateya; Tomoko Tateya; Seong Hee Choi; Diane M Bless
Journal:  J Speech Lang Hear Res       Date:  2009-08       Impact factor: 2.297

7.  Reduced FOXO1 expression accelerates skin wound healing and attenuates scarring.

Authors:  Ryoichi Mori; Katsuya Tanaka; Maiko de Kerckhove; Momoko Okamoto; Kazuya Kashiyama; Katsumi Tanaka; Sangeun Kim; Takuya Kawata; Toshimitsu Komatsu; Seongjoon Park; Kazuya Ikematsu; Akiyoshi Hirano; Paul Martin; Isao Shimokawa
Journal:  Am J Pathol       Date:  2014-07-08       Impact factor: 4.307

8.  Co-localization of LTBP-2 with FGF-2 in fibrotic human keloid and hypertrophic scar.

Authors:  Mohamed A Sideek; Abdulrahman Teia; Zlatko Kopecki; Allison J Cowin; Mark A Gibson
Journal:  J Mol Histol       Date:  2015-12-07       Impact factor: 2.611

9.  FGF2-mediated attenuation of myofibroblast activation is modulated by distinct MAPK signaling pathways in human dermal fibroblasts.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  J Dermatol Sci       Date:  2017-09-01       Impact factor: 4.563

Review 10.  Fibroblast Growth Factor 2 as an Antifibrotic: Antagonism of Myofibroblast Differentiation and Suppression of Pro-Fibrotic Gene Expression.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  Cytokine Growth Factor Rev       Date:  2017-09-23       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.